Our Beliefs and Business Model

QOL Medical is a patient-centric company founded in 2003 to focus on the acquisition and commercialization of orphan products in underserved markets. QOL Medical ensures on expanded clinical awareness and patient access for improved quality of life in the treatment of rare and orphan diseases. The Company currently markets three FDA-approved products including Sucraid^®, Ethamolin^®, and Elliotts B^® Solution.

In 2010, QOL Medical was restructured with new management to focus on both the growth of existing products through broader disease and product awareness and the addition of new, therapeutically complimentary products. Although QOL Medical has owned as many as five products at one time and has divested several products, such as Nascobal^®, to larger pharmaceutical companies after demonstrating growth possibilities, the Company has changed its strategy with the restructuring to a focus on long-term relationships within specific therapeutic areas including metabolic diseases and pediatric gastroenterology.

QOL Medical’s primary product is Sucraid^®, a treatment for a rare, genetic, gastrointestinal disease known as congenital sucrase-isomaltase deficiency (CSID). QOL currently has 17 specialty sales reps (expanding to 30 sales reps in 2012) for Sucraid^®, through a co-marketing agreement targeting adult and pediatric gastroenterologists in concert with new, better clinical data and improved diagnostic tools.

QOL Medical has a management team with extensive partnering, acquisition and divestiture experience in the pharmaceutical and other industries, as well as a world-class network of scientific and medical advisors. The Company is interested in acquiring and partnering with pharmaceutical assets in late Phase II through commercially approved stages in the metabolic and pediatric gastrointestinal therapeutic areas.